Congratulations to the Clinical Genetics research team for successfully recruiting more that 100 people to an interventional research trial called ALDO – Avoiding Late Diagnosis in Ovarian Cancer.
This trial focuses on improving the care pathway for women over 35 who carry a mutation in the BRCA1 and/ or BRCA2 gene and are therefore at a high risk of developing ovarian cancer (OC). Many women delay having surgery for a number of reasons such as wanting to complete their family, avoid early menopause and associated symptoms / problems. This trial is for women who delay having surgery and opt for surveillance with a 4 monthly blood test testing for CA-125, a protein which increases in cases of ovarian cancer. The result of the CA-125 is then analysed by the ROCA Test, which tells how likely it is that they currently have an ovarian cancer. The ROCA Test calculates their risk, by looking at age, menopause status and previous CA-125 levels if there are any.
This study opened in August 2018 and has a short recruitment window, until end of 2018. The team have now recruited over 100 patients. Guy’s and St Thomas’ were the highest recruiting centre in the UK and hope more of our eligible patients will take up their invitation to participate.
- Be a woman aged 35 or over
- Have a known BRCA1 or BRCA2 mutation
- Had not had both ovaries removed. (Women can have still take part if they have only had one ovary removed, or if they have had one or both fallopian tubes removed)
- Are willing to travel to one of the centres involved in the project should they be called for any follow-up investigations.
Please contact Amy Day to find out how you can participate in the trial.